Substance / Medication

Porcine factor VIII

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
Türkantoz Halet, Königs Christoph, Knöbl Paul et al. · J Thromb Haemost · 2020
PMID: 31448877Observational
The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice.
Healey John F, Parker Ernest T, Barrow Rachel T et al. · Thromb Haemost · 2009
PMID: 19572065ObservationalFull text (PMC)
Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.
Parker E T, Craddock H N, Barrow R T et al. · J Thromb Haemost · 2004
PMID: 15102015Observational
Porcine factor VIII: pharmacoeconomics of inhibitor therapy.
Ewenstein B M, Avorn J, Putnam K G et al. · Haemophilia · 2002
PMID: 11882077Observational
Acquired Hemophilia A Treated with Recombinant Porcine Factor VIII: Case Report and Literature Review on Its Efficacy.
Borro Matteo, Tassara Riccardo, Paris Luca et al. · Hematol Rep · 2023
PMID: 36648881Case ReportFull text (PMC)
Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review.
Hayden Alexander, Candelario Nellowe, Moyer Genevieve · Res Pract Thromb Haemost · 2022
PMID: 35356668Case ReportFull text (PMC)
Treatment of acquired haemophilia with recombinant porcine factor VIII: A successful strategy in a patient with unstable angina.
Owen Mary, Gidley Gillian, Horn Elizabeth H · Haemophilia · 2019
PMID: 30604899Case Report
Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
Croteau S E, Abajas Y L, Wolberg A S et al. · Haemophilia · 2017
PMID: 28124406Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Porcine factor VIII (substance)
SNOMED CT
418614009
UMLS CUI
C0724529

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.